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Objectives: Anti-cancer chemotherapeutic pharmaceutical agents have some 
toxic effects to normal cells. Therefore, the main factors to increase therapeutic 
effects are to destroy cancer cells specifically and appropriate dosage of anti-
cancerous agents. Cancer cells are have being studied in many ways by using cell 
culture technologies in developed countries. We aimed to determine the chemo-
sensitivity of colorectal cancer cases. MethOds: From February 2013 through 
February 2014, Histoculture drug response assay data were obtained from 6 colo-
rectal cancer surgical specimens held in State Central Hospital. Cultures and 
culture media were prepared by R. Hoffmans methods. We examined chemosen-
sitivities of the tissue to carboplatin, irinotecan, doxorubicin, 5-fluorouracil and 
oxalaplatin. Cutoff inhibition rates were determined with each drug for colorectal 
cancer and were used to calculate predictabilities for chemosensitivity responses. 
We also prepared double samples from the culture and made histologic and cyto-
logic analysis. Results: The evaluability of the histoculture drug response assay 
was at 83,3%. Predictability including true-positive and true-negative rates of 83,3% 
and 100% was observed. cOnclusiOns: Cancer cells deaths are dependent from 
dosages of the candidate medications and it shows it is possible to use drug sen-
sitivity methods in oncologic clinical practice.
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Objectives: Various studies exploring the routine use of corticosteroids for man-
agement of acute respiratory distress syndrome have had controversial results. 
The aim of this study was to evaluate and compare randomized, controlled trials 
with observational studies (comparing historical controls) determining the effi-
cacy and safety of steroids in management of Acute Respiratory Distress Syndrome 
in adult population. MethOds: English language, randomized control trial and 
observational studies were searched using different  databases like the Cochrane 
Central Register of Controlled Trials, Cochrane database of systematic reviews, 
PUBMED, SCOPUS, SCIENCE DIRECT (Key terms: corticosteroids, methylprednisolone, 
hydrocortisone, dexamethasone AND acute lung injury, adult respiratory distress syn-
drome, acute respiratory distress syndrome, ARDS, respiratory failure, septic shock; years: 
inception to February 2014). Results: A total of 8 randomized control trial and 5 
observational studies using variable dose and duration of steroids met the inclu-
sion criteria. The Mantel-Hanzel odds ratio of corticosteroids decreasing mortality 
in patients of randomized, controlled trial was 0.822; 95% CI 0.480 to 1.408 whereas 
in observational studies was 0.552; 95% CI 0.134 to 2.278. The odds of corticoster-
oids associated infectious complications in patients of randomized, controlled 
trial was 1.118; 95% CI 0.557 to 2.247 whereas in observational studies was 1.662; 
95% CI 0.981 to 2.816. cOnclusiOns: A definitive role of corticosteroids in ARDS 
has not been established. However, current data from studies shows the result 
favouring use of corticosteroids in ARDS by decreasing the mortality associated. 
However, use of steroids is associated with a slight risk of increased infectious 
complications.
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Objectives: Acute respiratory distress syndrome (ARDS) is an acute hypoxemic 
respiratory failure. It is the most severe form of acute lung injury. The treatment 
of ARDS is generally supportive and there is ambiguity in the role of glucocorti-
coids in the treatment of ARDS. This study aimed at analyzing treatment pattern 
and outcome of patients in ARDS. MethOds: A retrospective observational study 
was conducted in a tertiary care teaching hospital. All the patients diagnosed 
with ARDS confirmed by chest X-ray and arterial blood gas during 2011 were 
included. Cases were identified and collected from the medical records division 
using ICD code J86. Results: A total of 150 patients diagnosed with ARDS were 
included in the study. Mean age of the study population was 43.37 ± 16.15 years. 
Majority of them were males, 60.7% of the population. Analyzing the treatment 
pattern, 98.6% were given antibiotics for their underlying conditions along with 
supportive therapies, 48.6% of patients received glucocorticoid therapy and was 
found to be beneficial. Outcome analysis revealed 50.7% of patients recovered 
and 45.3% expired. Higher mortality (56.4%) was observed in the group who did 
not receive glucocorticoid therapy compared to the group which received gluco-
corticoid therapy (41.7%). cOnclusiOns: The overall mortality rate was found 
to be high in ARDS patients in this study and use of glucocorticoids showed ben-
eficial effects.
Objectives: The aim of this study was to analyze the tuberculosis-related medical 
resource utilization pattern among new smear positive pulmonary tuberculosis 
(PTB) patients. We also estimated the cost of tuberculosis (TB) treatment from the 
perspective of provider and patient, and identified the significant cost driving fac-
tors. MethOds: All new smear positive PTB patients who were registered at the 
chest clinic of Penang General Hospital, between March 2010 and February 2011, 
were invited to participate in the study. Provider sector costs were estimated using 
bottom-up, micro-costing technique. For the calculation of costs from the patients’ 
perspective, all eligible patients who agreed to participate in the study were inter-
viewed after the intensive phase and at end of their treatment by a trained nurse. 
Predictive Analysis SoftWare was used to analyze the data. Results: During the 
study period, 226 patients completed the treatment. However, complete costing 
data were available for 212 patients. The most highly utilized resource was chest 
X-rays followed by sputum smear examination and non-specific laboratory tests. 
Only a smaller proportion of the patients were hospitalized. The total cost of treat-
ing a smear positive PTB patient was USD 727.24. The amount paid by the patient 
constituted 55.3% (USD 401.90) of the total average cost of TB treatment. In multiple 
linear regression analysis, prolonged treatment duration (i.e., > 6 months) was the 
only predictor of higher provider sector cost, whereby higher patient sector cost 
were determined by greater household income and persistent cough at the end of 
the intensive phase of the treatment. cOnclusiOns: The average provider sector 
cost was 1.45 times higher (USD 325.35 versus USD 225.00) than the budget allocated 
by the Ministry of Health for the treatment of a TB case in Malaysia. The expenses 
borne by the patients and their families accounted for 5.71% of their annual family 
income, hence not catastrophic.
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Objectives: Chronic diseases are common and costly to society, but often pre-
ventable. This study focuses on better understanding awareness and prevention of 
chronic diseases in Japan. MethOds: This study included data for the 2012 Japan 
(N= 30,000) National Health and Wellness Survey, a cross-sectional, Internet-based 
survey of adults (18+ years) who provide information on their comorbidities, and 
health care behaviors. Awareness of chronic diseases were assessed using the 
following question: “Which of the following conditions are you aware of (COPD, 
depression, diabetes, hypertension, dyslipidemia and osteoporosis)?”. Prevention 
was assessed with the following question: “Which conditions to do take steps to 
prevent (heart attack/heart problems/stroke/mini-stroke, diabetes, osteoporosis)?”. 
Risk groups of COPD, depression, diabetes, hypertension, dyslipidemia and osteo-
porosis were calculated. Results were weighted/projected to represent the total 
population based on the Census Bureau. Results: In Japan, 19.8%, 79.1%, 78.4%, 
77.6%, 63.2%, 71.0% report awareness of COPD, depression, diabetes, hypertension, 
dyslipidemia, and osteoporosis, respectively. Within the risk groups only 25.1%, 
82.7%, 87.0%, 82.4%, 81.9%, 81.1% report awareness of COPD, depression, diabetes, 
hypertension, dyslipidemia, and osteoporosis, respectively. Overall, 4.4% of respond-
ents were taking steps to prevent heart problems, 7.7% were taking steps to prevent 
diabetes and 5.7% were taking steps to prevent osteoporosis. Among the COPD risk 
group, 36.5% quit smoking and 41.8% of the depression risk group spoke to a health 
care provider in the past six months. Within the diabetes risk groups 46.8% were 
taking steps to prevent diabetes. Only 6.5% of hypertension and 7.7% of dyslipidemia 
risk respondents were taking steps to prevent heart problems. In the osteoporosis 
risk group only 15.5% where taking steps to prevent osteoporosis. cOnclusiOns: 
Data suggests a need for education programs to build awareness of chronic diseases 
in Japan. Due to the lack of knowledge of chronic diseases in Japan, prevention is 
limited especially amongst the at risk groups.
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Objectives: The purpose of this study was to examine cost-effectiveness of 
varenicline, a pharmacotherapy developed to support smoking cessation, versus 
currently available alternatives. MethOds: Two analytic decision tree models were 
used to simulate effectiveness of varenicline versus bupropion and varenicline ver-
sus nicotine replacement therapy (NRT). A 30-year Markov model with health states 
“Smoker”, “Quitter” and “Dead” was used for a hypothetical cohort of Korean smok-
ers who are over 30 years old and willing to quit smoking. The population entered in 
the model received three months of therapy. Utility values of smokers and quitters 
incorporated in the model were collected from local data. Transition probabilities 
were from clinical trials and local statistic data, and cost data were obtained from 
Korean health insurance reimbursement price list and local market price for non-
reimbursement products. The model used a 5% discount rate for costs and effective-
ness. Sensitivity analyses were conducted on various parameters such as the time 
to reach mortality rate of ex-smokers compared to that of non-smokers, time hori-
zon and discount rate. Results: The effectiveness of varenicline compared with 
bupropion and NRT was greater while it was more costly than both. The incremental 
effectiveness of varenicline versus bupropion and NRT was similar at 77,965 QALYs. 
The incremental cost of varenicline versus bupropion was 826 billion KRW and 
1,428 billion KRW with NRT. The ICER of varenicline comparing to bupropion and 
NRT were estimated at 10.6 million KRW per QALY and 19 million KRW per QALY, 
respectively. Sensitivity analyses were quite robust for all parameters but it was 
most sensitive to time horizon. cOnclusiOns: Varenicline treatment for smoking 
cessation can be considered as cost-effective compared with existing therapies in 
Korea. The ICER becomes lower when morbidity rates of smoking related diseases 
are reflected.
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Objectives: Multiple myeloma (MM) is known as an incurable cancer of plasma 
cells, which incurs significant burden on patients. There are estimated 27,000 MM 
patients in China in 2013, and the incidence is 1–4 per 100,000 people per year. 
However, the disease burden of MM in China has not been well studied. Using 
Guangzhou claim data, this article estimated the economic burden on patients with 
MM from a societal perspective. MethOds: 2009-2011 databases of Urban Employee 
Basic Medical Insurance and Urban Residents Basic Medical Insurance were used to 
estimate the direct medical cost of MM and the determinants of medical cost. The 
direct medical costs of bortezomib-based therapies and regular chemotherapies 
were compared. Disability Adjusted Life Year (DALY) was used to estimate the indi-
rect cost. Results: For a patients with MM conditions in Guangzhou, the direct cost 
was RMB 8.45 million in 2009, 8.52 million in 2010, and 13.90 million in 2011, while 
the indirect cost was RMB 12.18 million, 13.11 million, and 19.46 million, respectively. 
Moreover, the MM medical cost was higher with age, increasing reimbursement 
rate and length of stay. The average hospitalization expenditure for bortezomib-
based therapies and regular chemotherapies were RMB 60,945.84±38,335.12 and 
16,465.62±19,695.13 (P< 0.001). The out-of-pocket (OOP) cost for per treatment cycle 
were significantly higher for patients treated with bortezomib-based therapy (RMB 
43,773.57±12,415.07) than for those treated with regular chemotherapies (RMB 
3,720.74±4,060.65). cOnclusiOns: MM conditions have serious economic burdens, 
and was significantly increased overtime in China.MM patients would pay over 12 
times more OOP cost for the use of bortizomib-based therapy than for the use of 
commonly-used chemotherapies.
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Objectives: To investigate the health care utilization and cost, focusing on the use 
of oral anti-diabetic drugs (OADs) for type 2 diabetes patients in China. MethOds: 
A large scale, prospective, and observational study was conducted in 5 cities of 
China. Subjects on any OAD were enrolled. The data was collected from longitu-
dinal interviews and diary following-up with the enrolled patients. Primary data 
information included socio-demographic characteristics, health care and medica-
tion utilization and costs, laboratory assessments, and quality of life. The baseline 
interview and 4 times of following-up were conducted within 12 months. HbA1c, 
fasting blood-glucose and blood lipids were assessed. Multivariable regression and 
propensity score matching methods were used to control for confounding factors 
in the study. Results: 2886 patients enrolled at baseline, 2322 of them completed 
the full study. The average age of enrolled patients at baseline was 61.71(sd= 11.27) 
years. The number of OADs per patient was 1.66 (sd= 0.80) with a median of 2. The 
mostly used 4 OADs are: Metformin (44.01%), Acarbose (28.64%), XIaoke Pill (a tra-
ditional Chinese medicine, 20.54%) and Gliclazide (18.26%). On average, a patient 
spent CNY 8,867.56 (sd= 17,642.51) on health care annually, where OADs cost CNY 
2,645.82 (sd= 3,123.30). When controlling for other confounding variables via statisti-
cal models, further analysis finds that patients on XIaoke Pill as the major regimen 
ended up with a reduction in total health care cost by CNY 2,151 (p< 0.01), where 
OADs cost was reduced by about CNY 626 (p< 0.01). cOnclusiOns: Type 2 Diabetes 
patients in China bear a heavy economic burden. Among OADs, traditional Chinese 
medicine Xiaoke Pill appears to be a quite cost effective treatment regimen for 
diabetic patients in China. Future analysis is warranted to investigate mechanisms 
and conditions through which oral Chinese OADs may be cost effective for some 
diabetic patients in China.
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Objectives: To describe the methodologies used in health economics (HE) studies 
on Parkinson’s disease (PD) in China. MethOds: A structured literature review was 
conducted to describe the methodology used to generate HE evidence for PD treat-
ment in China. The review was conducted in both English and Mandarin languages 
using four databases: PubMed, Cochrane, WAN FANG and VIP, for articles published 
between 2000 and 2013. Study selection was limited to Chinese population based 
in China and those which reported cost-effectiveness ratio (CER) or incremental 
cost-effectiveness ratio (ICER) of PD pharmacotherapy. Results: Six studies were 
selected, all in mandarin. The studies were conducted using different study designs 
including cohort, randomised controlled trials (RCT) and retrospective observation. 
None of the studies utilised any HE modelling. Cost-effectiveness comparisons were 
made between levodopa monotherapy with or without benserazide against other 
adjuvant PD pharmacotherapies. Two studies were conducted based on health sys-
tem perspectives, 2 studies on societal perspectives and the remaining 2 studies 
did not report any. Cost components calculated differed between studies. Only 2 
studies investigated the cost-effectiveness of PD treatment using both direct and 
indirect costs. The effectiveness outcomes were mostly determined using either 
Unified Parkinson’s disease Rating Scale (UPDRS), followed by Parkinson’s disease 
Questionnaire (PDQ) or Visual Analogue Quality of Life (VAS-QOL) scale. Only one 
study reported ICER value whereas the remaining studies only reported CER. All 
studies conducted primary data collection for the purpose of the cost-effectiveness 
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Objectives: Being from the very land and a son of the same soil. Africa is the 
world’s second-largest also the most poorest most underdeveloped continent. 
With great struggles and constraints in provision of essential drugs and program 
initiatives,its hard to make proper intervention in urgent essential needs of rem-
edies required on a daily basis especially in the wider scope of village population 
on health priorities. MethOds: In 2007, Africa’s dialysis population constituted 
only 4.5% of the world’s dialysis population, with a prevalence of 74 per million 
population (pmp), compared to a global average of 250 pmp. In almost half the 
African countries, no dialysis patients are reported. The prevalence of peritoneal 
dialysis (PD) was 2.2 pmp, compared to a global prevalence of 27 pmp, with the bulk 
of African PD patients (85%) residing in South Africa. In North African countries, 
which serve 93% of the Results: African dialysis population, the contribution of 
PD to dialysis is only 0% – 3%. Cost is a major factor affecting the provision of 
dialysis treatment and many countries are forced to ration dialysis therapy. Rural 
setting, difficult transportation, low electrification rates, limited access to improved 
sanitation and improved water sources, unsuitable living circumstances, and the 
limited number of nephrologists are obstacles to the provision of PD in many coun-
tries. cOnclusiOns: The potential for successful regular PD programs in tropical 
countries has now been well established. Cost is a major prohibitive factor but the 
role of domestic manufacture in facilitating widespread use of PD is evidenced by 
the South African example. Education and training are direly needed and these are 
areas where international societies can be of great help.
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Objectives: Though Chinese herbal medicine had been proofed effective in clinical 
practice, due to the lack of suitable outcomes, the current randomised controlled 
trial studies (RCT) mostly stated that Chinese herbal formulas uneffective, thus the 
effectiveness are rarely confirmed publicly. In this study we applied Chinese syn-
dromes in the effectiveness evaluation of Chinese herbal formulas and to assess their 
suitability and necessity. MethOds: In an finished RCT research, angina patients 
with Phlegm and Blood stasis syndrome were randomized into experimental group 
(Chinese herbal formulas combined with western basic therapy) and placebo group 
respectively. An Chinese questionnaire TCM-SAQ, Seattle Angina Questionnaire (SAQ), 
and SF-12 were applied as patients reported outcomes to evaluate the effectiveness. 
And the results shows that there is no statistical difference in SF-12 and SAQ between 
two groups after 8 weeks’ treatment, while there is significant difference shown in 
the syndrome domain of TCM-SAQ. On the basis of these results, the deviation value 
of all the domains in each questionnaire from the baseline to after 8 weeks’ treat-
ment were calculated. And then the Pearson correlation of the deviation value among 
the domains in TCM-SAQ with domains in SAQ and SF-12 were analysed. Results: 
The correlation between angina domain in TCM-SAQ with each domain in SAQ and 
SF-12 is from 0.045 to 0.237 (p< 0.01), physical limitation domain is 0.450 to 0.779 
(p< 0.01), sleep quality domain is 0.342 to 0.555(p< 0.01), Chinese syndrome domain is 
0.477 to 0.688 (p< 0.01), worry of disease domain is 0.439 to 0.709 (p< 0.01), treatment 
satisfaction domain is 0.298 to 0.689 (p< 0.01). For Chinese syndrome domain the 
correlation with domains in SAQ and SF-12 were all higher than 0.4 and lower than 
0.7. cOnclusiOns: As an patients reported outcome, Chinese syndrome can reflect 
the effectiveness of Chinese herbal formulas. And it is in some degree suitable and 
necessary in the effectiveness evaluation of Chinese herbal formulas.
PRM7
a novel BRoadly aPPlicaBle Risk scoRe foR PRedicting MoRtality of 
Patients with ciRculatoRy systeM diseases within hosPitalization 
duRation
Qu Z.1, Song J.1, Zhan S.2, Ma X.1
1peking University, Beijing, China, 2peking University, Beijing, Beijing, China
Objectives: The common comorbidity indexes was developed about two dec-
ades ago and were not appropriate for inpatients risk adjustment nowadays. Our 
objective was to develop a risk stratification model that broadly predicts mortality 
risks in hospitalized patients with circulatory system diseases. MethOds: The 
risk score model was generated by using inpatient summary report of electronic 
medical record dataset from 2006 to 2010 among 50 tertiary hospitals in Beijing, 
and validated by same dataset of 65 tertiary hospitals in the whole country in 
2012. The patient diagnosis as identified by using the International Classification of 
Diseases, 10th Revision. Risk score was developed with individual major diagnostic 
codes. Receiver operating characteristic (ROC) analysis was used to evaluated the 
predictive effect of risk score, and the Charlson Comorbidity Index (CCI) was used 
to compare with the risk score in validation data sets. Results: The diagnosis code 
of total 4,216,375 patients were used to generate the risk scores which comprise 293 
items out of more than 4,000 categories and ranged from 96 to 1. In the validation 
data set, the ROC was 0.845 compared with the CCI ROC of 0.748 among myocardial 
infarction inpatients, and in coronary artery bypass grafting(CABG) inpatients the 
ROC was 0.729 to CCI ROC of 0.626, in percutaneous coronary intervention(PCI) 
inpatients the ROC was 0.847 and 0.648 respectively. The ROC of novel risk score 
was improved 12.7, 16.4 and 30.1 percent among inpatients with circulatory system 
disease. cOnclusiOns: This study generated a broadly applicable tool for risk 
adjustment that predicts circulatory system diseases inpatient mortality with more 
reliability than current risk indexes. This risk index will allow comorbidity-adjusted 
outcomes broadly in surgery, hospitalization and drug efficacy evaluation.
